Claim 30% Off Global Market Reports With Code ONLINE30 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

What Is The Current Size And Growth Outlook For The Huntington’s Disease Treatment Market?

The market size of treatment for Huntington’s disease has experienced rapid expansion in the past few years. The market, which is expected to increase from $0.73 billion in 2024 to $0.82 billion in 2025, forecasts a compound annual growth rate (CAGR) of 12.3%. Factors contributing to the growth in the previous period include an amplified awareness towards genetic diseases, improvements in the availability of genetic testing, increased funding towards research of neurodegenerative diseases, a higher count of clinical trials for experimental treatments, and a burgeoning stream of drugs designed to modify the disease.

In the years to come, the Huntington’s disease treatment market is anticipated to experience a rapid expansion. This growth is predicted to reach $1.32 billion in 2029, with a compound annual growth rate (CAGR) of 12.6%. The expansion through this period can be correlated to the increasing emphasis on personalized medicine, amplified integration of digital health monitoring, escalating regulatory support for orphan drugs, a surge in demand for symptomatic relief therapies, and a growing call for disease-modifying treatments. Tops trends projected for the period include the emergence of technology-driven gene silencing tools, the development of cell-based therapies and peripheral biomarkers, the incorporation of telehealth in HD management, the amalgamation of patient-reported outcomes, and advancements in disease-modifying drugs.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24245&type=smp

Which Factors Are Steering Growth In The Huntington’s Disease Treatment Market?

The surge in gene therapies is seen as a catalyst for the future expansion of the treatment market for Huntington’s disease. These therapies, which adjust or replace faulty genes to preemptively combat or cure diseases at their genetic root, are gaining traction alongside advancements in precision medicine. This tech enables the direct addressing of genetic origins and as such, brings about superior results to traditional remedies. These therapies specifically combat Huntington’s disease by suppressing the defective HTT gene, which spawns harmful proteins and causes damage to nerve cells. This method is effective in decelerating the disease’s progress, safeguarding brain function, and possibly providing long-term control. For example, in July 2023, according to data reported by the American Society of Gene & Cell Therapy (ASGCT), a professional membership organization based in the US, and Citeline, a US-based supplier of medication and medical equipment, the number of phase II gene therapies had risen to 260 by the Q2 2023, a 5% increase from 247 at the end of Q1. Thus, this rise in gene therapies is catalyzing the expansion of the Huntington’s disease treatment market.

What Are The Key Segment Trends Observed In The Huntington’s Disease Treatment Market?

The huntington’s disease treatment market covered in this report is segmented –

1) By Treatment: Symptomatic Treatment, Disease-Modifying Therapies

2) By Administration Type: Oral, Intravenous, Subcutaneous, Topical

3) By Therapeutic: Genetic Disorders, Neurological Disorders, Psychiatric Disorders

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End-User: Hospitals, Clinics, Homecare Settings, Research Centers

Subsegments:

1) By Symptomatic Treatment: Antidepressants, Antipsychotics, Mood Stabilizers, Chorea Medications, Cognitive Enhancers

2) By Disease-Modifying Therapies: Gene Therapy, Neuroprotective Agents, RNA-Based Therapies, Stem Cell Therapy, Protein-Targeting Therapies

Which Disruptive Trends Are Driving Change Across The Huntington’s Disease Treatment Market?

Leading businesses in the Huntington’s disease treatment market are concentrating on the advancement of high-level therapies such as selective vesicular monoamine transporter 2 (VMAT2) inhibitor capsules. These capsules aim to enhance the patient’s lifestyle while curbing the progression of the disease. Selective VMAT2 inhibitor capsules are drugs that obstruct the vesicular monoamine transporter 2, a protein crucial in composing neurotransmitters for brain discharge. These medications assist in lessening the release of neurotransmitters, therefore, controlling involuntary movements and associated symptoms. For example, in August 2023, the U.S. Food and Drug Administration (FDA) gave Neurocrine Biosciences, Inc., a US-based biotech enterprise, approval for Ingrezza (valbenazine) capsules, which are a once-daily oral VMAT2 inhibitor. These capsules combat chorea linked with Huntington’s disease (HD) in adults by mitigating excessive dopamine signaling in the brain. The drug is procurable in various capsule strengths and is suitable for intake with or without food, providing a flexible dosing alternative for patients.

Which Firms Are Driving Innovation Within The Huntington’s Disease Treatment Market?

Major companies operating in the huntington’s disease treatment market are F. Hoffmann-La Roche Ltd., Novartis AG, Teva Pharmaceutical Industries Ltd., Vertex Pharmaceuticals Incorporated, Bausch Health Companies Inc., Sun Pharmaceutical Industries Inc., H. Lundbeck A/S, WaVe Life Sciences Ltd., Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals plc, Lupin Limited, Neurocrine Biosciences Inc., Alnylam Pharmaceuticals Inc., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., Annexon Inc., Uniqure NV, Sage Therapeutics Inc., Azevan Pharmaceuticals Inc., Prilenia Therapeutics B.V.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/huntingtons-disease-treatment-global-market-report

What Regional Factors Are Accelerating Growth In The Huntington’s Disease Treatment Market?

North America was the largest region in the Huntington’s disease treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the huntington’s disease treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=24245&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model